OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Cancer is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Engineering growth factor ligands and receptors for therapeutic innovation	348
Revumenib: a new era in acute leukemia treatment	221
Subscription & copyright page	218
FBXW10: a male-biased E3 ligase in liver cancer	202
Spliced to kill: RNA mis-splicing derived cancer neoantigens	181
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy	179
Platelets: tailoring metastasis treatment	173
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	167
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	164
Tumor-resident microbes: the new kids on the microenvironment block	158
Navigating life as an early career researcher	156
Subscription and copyright page	156
Advisory Board and Contents	150
Subscription & copyright page	137
Accessing the vasculature in cancer: revising an old hallmark	137
Leveraging circulating microbial DNA for early cancer detection	137
Engine shutdown: migrastatic strategies and prevention of metastases	127
Onco-condensates: formation, multi-component organization, and biological functions	127
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	125
Radiotherapy and immunotherapy: open questions and future strategies	114
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	109
Benefits and opportunities of the transgenic Oncopig cancer model	92
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	91
Tumor immunology CRISPR screening: present, past, and future	88
GOT2 consider the tumor microenvironment	87

Subscription & copyright page	85
Chromosomal instability and aneuploidy as causes of cancer drug resistance	80
Pannexin biology and emerging linkages to cancer	80
Crosstalk of T cells within the ovarian cancer microenvironment	78
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	77
Chromatin as an old and new anticancer target	76
Oncogenic competence: balancing mutations, cellular state, and microenvironment	75
Neural hijacking in cancer metabolism: from nutrients to organelles	73
Cell death, therapeutics, and the immune response in cancer	72
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	70
Gut microbiota – a double-edged sword in cancer immunotherapy	69
Recent developments in myeloid immune modulation in cancer therapy	69
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	68
Diet, nutrient supply, and tumor immune responses	67
Regulation of metastatic organotropism	63
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	61
Advisory Board and Contents	60
Subscription & copyright page	58
Cancer catecholamine conundrum	57
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	56
Genetic immune escape in cancer: timing and implications for treatment	54
Subscription & copyright page	53
Advisory Board and Contents	53
Advisory Board and Contents	53
Scaling data toward pan-cancer foundation models	53
Inflammation: the incubator of the tumor microenvironment	52
Organellar pH as an emerging vulnerability to exploit in cancer	52
Insights on ErbB glycosylation – contributions to precision oncology	52
Palmitate paves the way to lung metastasis	52
Clinical and translational relevance of intratumor heterogeneity	51
The emerging field of oncolytic virus-based cancer immunotherapy	50
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence	49
Subscription & copyright page	48
Redefining precision cancer prevention to promote health equity	48
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer	47
Molecular and clinical insights into early-onset endometrial cancer	46
Advisory Board and Contents	46
Advancing cancer precision surgery with the tumor coagulome	46
Advisory Board and Contents	46
Subscription and copyright page	45
Advisory Board and Contents	43
B7-H3: a robust target for immunotherapy in prostate cancer	42
Emerging mechanisms of telomerase reactivation in cancer	42
Updating cancer research with patient-focused networks	42
Stress granules and hormetic adaptation of cancer	42
Advisory Board and Contents	42
Prospects for understanding and exploiting the consequences of hyperactivation lethality	42
RHOA takes the RHOad less traveled to cancer	42
Targeting the mitochondrial unfolded protein response in cancer: opportunities and challenges	41
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development	41

Advisory Board and Contents	41
Circulating cell-free DNA-based multi-cancer early detection	41
CAR T cell persistence in cancer	40
Advisory Board and Contents	40
Targeting TIM-3 to halt lung precancer progression	40
Advisory Board and Contents	40
Cross-dressing of dendritic cells strengthens antitumor immunity	39
Advisory Board and Contents	39
Time-of-day dependency of adoptive cell therapies	39
Subscription & copyright page	39
Beyond safety: suicide systems in cell-based cancer therapies	39
Dissecting liver tumor heterogeneity to improve health equity	38
A tipping point in cancer epidemiology: embracing a life course exposomic framework	38
A macrophage-neutrophil program drives mammary carcinogenesis	38
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations	38
The promise of TIL therapy for glioblastoma	38
RNA vaccines for cancer: revolutionizing immunization strategies	38
Leveraging space innovations for cancer breakthroughs on Earth	36
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes	36
Immune response and inflammation in cancer health disparities	36
Functional heterogeneity of fibroblasts in primary tumors and metastases	35
Branched chain amino acids and their aberrant metabolism in cancer	35
Neoantigen-directed therapeutics in the clinic: where are we?	35
Subscription & copyright page	34
Advisory Board and Contents	34
Space in cancer biology: its role and implications	33
Ferroptosis vulnerability in FLT3-mutant leukemia	33
Epigenetic basis and targeting of cancer metastasis	33
Advisory Board and Contents	32
Dying to survive: harnessing inflammatory cell death for better immunotherapy	30
Advisory Board and Contents	30
Tumor-draining lymph nodes – friend or foe during immune checkpoint therapy?	29
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	29
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	29
Engineered bacterial therapeutics for detecting and treating CRC	29
Clonal evolution and hierarchy in myeloid malignancies	29
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	28
Subscription & copyright page	28
Subscription & copyright page	28
Addressing the genetic/nongenetic duality in cancer with systems biology	28
Advisory Board and Contents	28
IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	28
The development of therapy related myeloid neoplasms in childhood cancer survivors	28
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	27
Genitourinary cancer neoadjuvant therapies: current and future approaches	27
NETscape or NEThance: tailoring anti-cancer therapy	27
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	26
Next-generation cancer vaccines and emerging immunotherapy combinations	26
Lifileucel: the first cellular therapy approved for solid tumours	26
Persisting cancer cells are different from bacterial persisters	25
IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression	25
Subscription & copyright page	25
Successfully targeting the cancer system with metronomics for medulloblastoma	25
Immunomodulation by endothelial cells: prospects for cancer therapy	25
Deciphering the roles of ABCB5 in normal and cancer cells	25
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome	24
How cancer cells make and respond to interferon-I	24
Tissue architecture in tumor initiation and progression	23
Future perspectives on engineered T cells for cancer	23
Embracing diversity: macrophage complexity in cancer	23
The extracellular matrix in cancer: from understanding to targeting	23
Think zebras: challenges and opportunities for treating rare cancers	22
Emerging and extensive clonal evolution in the pancreas	22
Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations	22
NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis	22
Enhancing dendritic cells by inhibiting BCL2	21
Bone marrow microenvironment: roles and therapeutic implications in obesity-associated cancer	21
Poised epigenetic states dictate metastatic fitness	21
New York’s Polyethnic-1000: a regional initiative to understand how diverse ancestries influence the risk, progression, and treatment of cancers	21
Subscription & copyright page	21
Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance	21
TET2, tumor control, and CAR T cell hyperproliferation	21